PT  - JOURNAL ARTICLE
AU  - Chang Liu
AU  - Binglu Cheng
AU  - Gang Zhao
AU  - Hengjie Yuan
TI  - Process analysis of anthracycline adverse reactions in breast cancer patients with postoperative chemotherapy
AID  - 10.1136/jim-2022-002339
DP  - 2022 Aug 01
TA  - Journal of Investigative Medicine
PG  - 1352--1357
VI  - 70
IP  - 6
4099  - http://hw-f5-jim.highwire.org/content/70/6/1352.short
4100  - http://hw-f5-jim.highwire.org/content/70/6/1352.full
SO  - J Investig Med2022 Aug 01; 70
AB  - This study aimed to explore the clinical adverse effects of anthracyclines on patients undergoing chemotherapy after breast cancer surgery. A total of 118 patients who received anthracycline chemotherapy after breast cancer surgery were selected as the research object, and the changes of echocardiogram, ECG, myocardial enzymes and blood biochemical indices before, during and after chemotherapy were studied. SPSS V.20 was used to conduct statistical analysis. The differences in heart rate, ST-segment abnormalities, creatine kinase, lactate dehydrogenase, hemoglobin, albumin, triglycerides and high-density lipoprotein were statistically significant. Heart rate and triglycerides increased significantly in the early stage of chemotherapy; ST-segment abnormality increased during the entire chemotherapy period; creatine kinase and lactate dehydrogenase increased significantly in the late stage of chemotherapy; hemoglobin and albumin decreased in the early stage of chemotherapy. The magnitude is large; high-density lipoprotein decreases throughout the chemotherapy period. In anthracycline chemotherapy regimens, bone marrow suppression and dyslipidemia occur in the early stage of chemotherapy, and the risk of cardiotoxicity is higher in the late stage of chemotherapy.Data are available upon reasonable request.